New Survival Data Keeps Roche Ahead In TIGIT Immunotherapy Race
But Can It Really Challenge Keytruda Dominance?
Executive Summary
Roche’s Phase II lung cancer results bode well for SKYSCRAPER readout expected in 2022.
You may also be interested in...
Roche’s Phase III TIGIT Failure In Metastatic SCLC Disappoints But Is Small Loss
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.
Readouts For TIGIT And Alzheimer’s Drugs Will Define Roche’s Year
Roche has a lot riding on it trials to extend use of Tecentriq to challenge Keytruda in frontline NSCLC – but the wait for its Alzheimer’s readout for gantenerumab will be truly nerve-wracking.
Investor Faith In David Hung’s Nuvation Renewed By Anheart Buyout
The acquisition brings two potential best-in-class cancer therapies, which could make Nuvation a commercial company as soon as 2025.